Ketamine Therapy For Internalizing Disorders: Is There A Single Mechanism?
This randomised controlled crossover Phase I trial (n=48) evaluated the safety and efficacy of ketamine for depression post-traumatic stress disorder obsessive-compulsive disorder phobic disorders using 35mg/70kg ketamine.
Detailed Description
Internalizing disorders, characterized by quiet, internal distress, include DSM5 diagnoses such as Generalized Anxiety Disorder, Social Anxiety Disorder, Major Depressive Disorder, Panic Disorder, Post-Traumatic Stress Disorder, Obsessive Compulsive Disorder and phobic states.
In contrast to slow and variable responsiveness to conventional medications, ketamine is rapidly effective in all internalizing disorders assessed so far. To account for these differences in speed of onset and breadth of activity between conventional treatments and ketamine, we have recently proposed a ‘double hit’ model for internalizing disorders, with 2 distinct forms of neural dysfunction to coincide. One hit, which is sensitive to ketamine, is disorder general: dysfunction of a neural system linked to high levels of the personality trait of neuroticism. The other hit is disorder-specific: dysfunction of one of a set of disorder-specific neural modules (already identified by theory), each with its own particular pattern of sensitivity to conventional drugs.
We predict that ketamine will produce similar right frontal EEG changes that will correlate with symptom improvement across all of these internalizing disorders. These findings will potentially provide clinicians and researchers with results that could produce major theoretical advances (e.g. for reclassification of anxiety and depressive disorders) and may support wider use of ketamine as a treatment for internalizing disorders.
Study Protocol
Preparation
Dosing
Integration
Study Arms & Interventions
Ketamine 0.5 mg/kg IM
experimentalSingle intramuscular racemic ketamine 0.5 mg/kg dose, one of three within-subject crossover treatment periods.
Interventions
- Ketamine0.5 mg/kgvia IM• single dose in one crossover period• 1 doses total
Ketamine 1.0 mg/kg IM
experimentalSingle intramuscular racemic ketamine 1.0 mg/kg dose, one of three within-subject crossover treatment periods.
Interventions
- Ketamine1 mg/kgvia IM• single dose in one crossover period• 1 doses total
Fentanyl 50 mcg IM
active comparatorSingle intramuscular fentanyl 50 mcg psychoactive control dose, one of three within-subject crossover treatment periods.
Interventions
- Placebo50 mcgvia IM• single dose in one crossover period• 1 doses total
Stored under placebo compound because fentanyl is a non-psychedelic psychoactive control, not a Blossom compound report.
Participants
Inclusion Criteria
- Capable of understanding and signing an informed consent
- diagnosed with one of the following DSM-5 diagnoses:
- post-traumatic stress disorder (PTSD) with a CAPS score >60;
- obsessive-compulsive disorder (OCD) with a YBOCS score >26;
- major depressive disorder (MDD) with a MADRS score >20;
- phobic state with FQ18 score >6
- Patients with PTSD, OCD or phobic state must not have MADRS scores >20 at screening.
- Patients must have had an inadequate response to prior treatment i.e. have not responded to at least two adequate trials of relevant medication and at least one trial of relevant psychotherapy.
Exclusion Criteria
- evidence of severe acute or chronic medical disorders,
- past or current diagnoses of schizophrenia, bipolar disorder, or current psychotic symptoms
- female patients who are pregnant or lactating
- drug use or dependence in the last 6 months
- current significant suicidal ideation
- prior history of seizures; susceptibility to photosensitivity; or a history of allergic skin reactions
Study Details
- StatusRecruiting
- PhasePhase I
- Typeinterventional
- DesignRandomizeddouble Blind
- Target Enrollment48 participants
- TimelineStart: 2020-11-02End: 2023-05-31
- Compounds
- Topic